GlassScriptPhysician profile
Guadalupe Lemus
NPI 1962803692
$7,109.69
in general payments reported to CMS, 2019-2025
28 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $987 · 2022: $841 · 2023: $1,589 · 2024: $2,318 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,198 · Education: $84.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,197.61 |
| Education | $84.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,160.68 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,125.25 | 2023-2025 | |
| Novo Nordisk INC | $996.08 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $714.47 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $637.42 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.44 | 2021-2025 | Jardiance, Ofev |
| Biohaven Pharmaceuticals, INC. | $355.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $242.36 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $218.66 | 2023-2024 | Linzess |
| Biohaven Pharmaceutical Holding Company LTD. | $172.60 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $164.33 | 2023-2025 | Rexulti |
| Pfizer INC. | $141.01 | 2023-2024 | |
| Abbott Laboratories | $136.56 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $111.30 | 2023-2024 | Otezla, Repatha |
| Philips North America LLC | $61.36 | 2025 | Vest Therapy Und |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $58.86 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $51.88 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $42.54 | 2025 | Voquezna |
| Agile Therapeutics, INC. | $34.74 | 2024 | Twirla |
| Mylan Specialty L.P. | $28.92 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $28.89 | 2022 | |
| Pulmonx Corporation | $23.40 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Hologic Sales and Service, LLC | $22.25 | 2025 | Thinprep 2000 Processor, Aptima |
| Idorsia Pharmaceuticals US INC | $22.17 | 2022 | |
| Shield Therapeutics INC | $20.13 | 2025 | |
| Glaxosmithkline, LLC. | $19.76 | 2024 | Nucala |
| Seqirus USA INC | $17.00 | 2025 | Fluad, Flucelvax |
| Exact Sciences Corporation | $15.63 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guadalupe Lemus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.